美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Aardvark Therapeutics

12.10

-0.1800-1.47%

盤後：12.100.00000.00%16:10 EST

成交量：6.68萬

成交額：80.75萬

市值：2.63億

市盈率：-5.39

高：12.52

開：12.18

低：12.00

收：12.28

52周最高：19.58

52周最低：4.88

股本：2,169.69萬

流通股本：588.80萬

量比：0.59

換手率：1.13%

股息：- -

股息率：- -

每股收益(TTM):-2.2430

每股收益(LYR):-0.7400

淨資產收益率：-48.06%

總資產收益率：-30.81%

市淨率：2.15

市盈率(LYR):-16.35

資料載入中...

總覽公司新聞資訊公告

Aardvark Therapeutics 成立美國子公司推進皮膚病產品管線發展；任命 Bryan Jones 為首席執行官

Aardvark Therapeutics宣佈向FDA提交併獲IRB批准其主打候選藥物ARD-101的修訂試驗方案，擴大普瑞德-威利綜合徵III期研究受試者資格

BUZZ--美國股票走勢-Invivyd、美國天然氣公司、新紀元能源公司

BUZZ-奧本海默將 Aardvark 評為 "跑贏大盤"，看好其差異化肥胖專營權

Aardvark Therapeutics Inc - 加拿大和英國的臨牀試驗地點已獲得註冊許可

Aardvark Therapeutics在澳大利亞進行的英雄三期試驗中宣佈首位患者接受治療

Aardvark Therapeutics宣佈FDA就擴大針對普拉德-威利綜合徵的三期Hero試驗人羣的協議修訂達成一致

美國研究綜述-Carvana、Marvell Technology、Wayfair

美國研究綜述-Carvana、Marvell Technology、Wayfair

LB 製藥公司在美國首次公開募股中籌資 2.85 億美元

生物技術行業陷入困境，LB Pharmaceuticals 着眼於 3.22 億美元的首次公開募股估值

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/AARD/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AARD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AARD\",,,,,undefined,":{"symbol":"AARD","market":"US","secType":"STK","nameCN":"Aardvark Therapeutics","latestPrice":12.1,"timestamp":1771016400000,"preClose":12.28,"halted":0,"volume":66780,"hourTrading":{"tag":"盘后","latestPrice":12.1,"preClose":12.1,"latestTime":"16:10 EST","volume":461,"amount":5578.1,"timestamp":1771017004661,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.014657980456026036,"floatShares":5888000,"shares":21696893,"eps":-2.243,"marketStatus":"總統日休市","change":-0.18,"latestTime":"02-13 16:00:00 EST","open":12.18,"high":12.52,"low":12,"amount":807508.542422,"amplitude":0.042345,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.243,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1771318800000},"marketStatusCode":7,"adr":0,"listingDate":1739509200000,"exchange":"NASDAQ","adjPreClose":12.28,"preHourTrading":{"tag":"盘前","latestPrice":12.15,"preClose":12.28,"latestTime":"09:29 EST","volume":5,"amount":60.75,"timestamp":1770992999909,"change":-0.13,"changeRate":-0.010586,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":12.1,"preClose":12.1,"latestTime":"16:10 EST","volume":461,"amount":5578.1,"timestamp":1771017004661,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.5867076204681116,"impliedVol":0.8949,"impliedVolPercentile":0.6471},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AARD\",,,,,undefined,":{"symbol":"AARD","floatShares":5888000,"roa":"-30.81%","roe":"-48.06%","lyrEps":-0.74,"volumeRatio":0.5867076204681116,"shares":21696893,"dividePrice":0,"high":12.52,"amplitude":0.042345,"preClose":12.28,"low":12,"week52Low":4.88,"pbRate":"2.15","week52High":19.58,"institutionHeld":0,"latestPrice":12.1,"eps":-2.243,"divideRate":0,"volume":66780,"delay":0,"ttmEps":-2.243,"open":12.18,"prevYearClose":13.125,"prevWeekClose":12.1,"prevMonthClose":12.99,"prevQuarterClose":13.125,"fiveDayClose":12.65,"twentyDayClose":15.35,"sixtyDayClose":10.36},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AARD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-13","symbol":"AARD","fiscalQuarterEnding":"2025/09","expectedEps":-0.82,"name":null,"time":"盤後","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-0.75},{"market":"US","date":"2025-08-13","symbol":"AARD","fiscalQuarterEnding":"2025/06","expectedEps":-0.52,"name":null,"time":"盤後","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"post","actualEps":-0.66},{"market":"US","date":"2025-05-14","symbol":"AARD","fiscalQuarterEnding":"2025/03","expectedEps":-0.7,"name":null,"time":"盤後","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":-0.71},{"market":"US","date":"2025-03-31","symbol":"AARD","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AARD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AARD\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AARD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AARD","date":"2026-02-13","current":-5.394561,"percent":0.891566,"low":-51.17654,"twenty":-10.700911,"median":-7.926792,"eighty":-5.956266,"high":-4.13394,"avg":-10.804592,"sd":8.94027,"marketCap":267375780},"quantilePoints":[{"date":"2025-02-21","current":-51.17654,"twenty":-46.993414,"median":-42.216938,"eighty":-39.920668,"marketCap":368880503},{"date":"2025-02-28","current":-39.75453,"twenty":-42.139802,"median":-40.229211,"eighty":-39.232381,"marketCap":286550651},{"date":"2025-03-07","current":-28.243517,"twenty":-40.603022,"median":-39.176012,"eighty":-36.900511,"marketCap":203579269},{"date":"2025-03-14","current":-31.091602,"twenty":-40.336014,"median":-37.766803,"eighty":-30.723725,"marketCap":224108270},{"date":"2025-03-21","current":-27.23482,"twenty":-39.944402,"median":-34.681377,"eighty":-29.198812,"marketCap":196308580},{"date":"2025-03-28","current":-26.404128,"twenty":-39.576524,"median":-30.913597,"eighty":-27.946841,"marketCap":190320955},{"date":"2025-04-04","current":-9.026143,"twenty":-39.119644,"median":-30.068072,"eighty":-27.341623,"marketCap":185830236},{"date":"2025-04-11","current":-7.397773,"twenty":-38.751766,"median":-29.400552,"eighty":-17.252871,"marketCap":152305358},{"date":"2025-04-17","current":-7.977371,"twenty":-38.300819,"median":-28.45119,"eighty":-8.603741,"marketCap":164238114},{"date":"2025-04-25","current":-8.66235,"twenty":-37.766803,"median":-27.946841,"eighty":-8.371497,"marketCap":178340462},{"date":"2025-05-02","current":-11.939711,"twenty":-36.900511,"median":-27.412825,"eighty":-8.371497,"marketCap":245814773},{"date":"2025-05-09","current":-11.307423,"twenty":-34.865316,"median":-26.68597,"eighty":-8.46634,"marketCap":232797221},{"date":"2025-05-16","current":-7.114571,"twenty":-32.693651,"median":-13.552046,"eighty":-8.46634,"marketCap":197215912},{"date":"2025-05-23","current":-7.834638,"twenty":-31.0204,"median":-11.823792,"eighty":-8.360959,"marketCap":217176159},{"date":"2025-05-30","current":-8.061615,"twenty":-30.818661,"median":-11.433881,"eighty":-8.172533,"marketCap":223467976},{"date":"2025-06-06","current":-9.353039,"twenty":-30.367714,"median":-11.107198,"eighty":-8.178795,"marketCap":259266244},{"date":"2025-06-13","current":-8.656453,"twenty":-30.076972,"median":-10.833207,"eighty":-8.210998,"marketCap":239956875},{"date":"2025-06-20","current":-9.454788,"twenty":-30.053238,"median":-10.188135,"eighty":-8.218152,"marketCap":262086713},{"date":"2025-06-27","current":-10.84796,"twenty":-29.697227,"median":-10.664596,"eighty":-8.356744,"marketCap":300705451},{"date":"2025-07-03","current":-10.894921,"twenty":-29.459887,"median":-10.613156,"eighty":-8.365174,"marketCap":302007206},{"date":"2025-07-11","current":-9.861782,"twenty":-29.308323,"median":-10.597502,"eighty":-8.375712,"marketCap":273368592},{"date":"2025-07-18","current":-9.360866,"twenty":-28.618005,"median":-10.433139,"eighty":-8.40036,"marketCap":259483203},{"date":"2025-07-25","current":-10.542714,"twenty":-28.285052,"median":-10.45662,"eighty":-8.474871,"marketCap":292244042},{"date":"2025-08-01","current":-9.4,"twenty":-28.006176,"median":-10.433139,"eighty":-8.577715,"marketCap":260567999},{"date":"2025-08-08","current":-9.368693,"twenty":-27.946841,"median":-10.061366,"eighty":-8.607418,"marketCap":259700162},{"date":"2025-08-15","current":-6.668132,"twenty":-27.567096,"median":-9.861782,"eighty":-8.474871,"marketCap":244307015},{"date":"2025-08-22","current":-5.762071,"twenty":-27.424692,"median":-9.803081,"eighty":-8.329026,"marketCap":211110768},{"date":"2025-08-29","current":-5.027748,"twenty":-27.270421,"median":-9.525229,"eighty":-8.145134,"marketCap":184206621},{"date":"2025-09-05","current":-5.027748,"twenty":-27.074615,"median":-9.478268,"eighty":-8.014507,"marketCap":184206621},{"date":"2025-09-12","current":-4.61321,"twenty":-26.629602,"median":-9.396086,"eighty":-7.797069,"marketCap":169018796},{"date":"2025-09-19","current":-6.685898,"twenty":-23.929853,"median":-9.368693,"eighty":-7.515801,"marketCap":244957921},{"date":"2025-09-26","current":-7.503129,"twenty":-17.043362,"median":-9.298251,"eighty":-7.308831,"marketCap":274899634},{"date":"2025-10-03","current":-9.102059,"twenty":-12.821851,"median":-9.210333,"eighty":-7.389343,"marketCap":333481245},{"date":"2025-10-10","current":-9.824539,"twenty":-12.161077,"median":-9.298251,"eighty":-7.460987,"marketCap":359951454},{"date":"2025-10-17","current":-7.876213,"twenty":-12.040618,"median":-9.212156,"eighty":-7.503145,"marketCap":288568676},{"date":"2025-10-24","current":-6.425331,"twenty":-11.978881,"median":-9.149542,"eighty":-7.334887,"marketCap":235411289},{"date":"2025-10-31","current":-6.194375,"twenty":-11.800608,"median":-9.102059,"eighty":-7.096882,"marketCap":226949500},{"date":"2025-11-07","current":-5.844979,"twenty":-11.619352,"median":-9.083015,"eighty":-6.739195,"marketCap":214148333},{"date":"2025-11-14","current":-6.453893,"twenty":-11.527382,"median":-8.978494,"eighty":-6.599437,"marketCap":236457733},{"date":"2025-11-21","current":-4.209833,"twenty":-11.386619,"median":-8.807467,"eighty":-6.451943,"marketCap":205321954},{"date":"2025-11-28","current":-4.455369,"twenty":-11.26527,"median":-8.719067,"eighty":-6.366112,"marketCap":217297254},{"date":"2025-12-05","current":-5.535729,"twenty":-11.176245,"median":-8.71121,"eighty":-6.20385,"marketCap":269988572},{"date":"2025-12-12","current":-6.968768,"twenty":-11.12541,"median":-8.663092,"eighty":-6.182531,"marketCap":339880775},{"date":"2025-12-19","current":-6.111623,"twenty":-11.06083,"median":-8.610671,"eighty":-6.174808,"marketCap":298076093},{"date":"2025-12-26","current":-6.366088,"twenty":-10.989171,"median":-8.599121,"eighty":-6.172233,"marketCap":310486858},{"date":"2026-01-02","current":-5.859391,"twenty":-10.980741,"median":-8.405995,"eighty":-6.111623,"marketCap":285774195},{"date":"2026-01-09","current":-6.477696,"twenty":-10.894921,"median":-8.362013,"eighty":-6.093766,"marketCap":315930176},{"date":"2026-01-16","current":-6.852697,"twenty":-10.894921,"median":-8.218152,"eighty":-6.111623,"marketCap":334219725},{"date":"2026-01-23","current":-6.732161,"twenty":-10.894921,"median":-8.171191,"eighty":-6.111623,"marketCap":328340941},{"date":"2026-01-30","current":-5.959837,"twenty":-10.857352,"median":-8.086731,"eighty":-6.108052,"marketCap":290673181},{"date":"2026-02-06","current":-5.040192,"twenty":-10.779084,"median":-8.030062,"eighty":-6.020346,"marketCap":245820240},{"date":"2026-02-13","current":-5.482157,"twenty":-10.700911,"median":-7.926792,"eighty":-5.956266,"marketCap":267375780}],"updateTime":1771271126440},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AARD\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1174773215","title":"Aardvark Therapeutics 成立美國子公司 推進皮膚病產品管線發展；任命 Bryan Jones 為首席執行官","url":"https://stock-news.laohu8.com/highlight/detail?id=1174773215","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174773215?lang=zh_tw&edition=fundamental","pubTime":"2026-02-12 21:06","pubTimestamp":1770901613,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics 宣布成立新的美国子公司，旨在支持其皮肤病产品管线的开发进程。公司同时宣布，任命 Bryan Jones 担任该子公司的首席执行官。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"1193243066","title":"Aardvark Therapeutics宣佈向FDA提交併獲IRB批准其主打候選藥物ARD-101的修訂試驗方案，擴大普瑞德-威利綜合徵III期研究受試者資格","url":"https://stock-news.laohu8.com/highlight/detail?id=1193243066","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193243066?lang=zh_tw&edition=fundamental","pubTime":"2026-02-10 21:05","pubTimestamp":1770728724,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics今日宣布，已向美国食品药品监督管理局（FDA）提交了其主打候选药物ARD-101的修订临床试验方案，并已获得机构审查委员会（IRB）的批准。此项修订旨在扩大针对普瑞德-威利综合征（PWS）的III期临床研究的受试者资格范围。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"2593473411","title":"BUZZ--美國股票走勢-Invivyd、美國天然氣公司、新紀元能源公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2593473411","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593473411?lang=zh_tw&edition=fundamental","pubTime":"2025-12-24 00:20","pubTimestamp":1766506822,"startTime":"0","endTime":"0","summary":"标普500指数.SPX上涨0.04%，报6881.36点；纳斯达克综合指数.IXIC下跌0.02%，报23425.18点。nL4N3XT0LJ ** Invivyd Inc IVVD.O:BUZZ - 因制药商开始COVID预防抗体的后期试验而上涨。nL4N3XT0M7 ** Freeport-McMoRan Inc FCX.N:BUZZ - 富国银行上调 Freeport-McMoRan PT，因铜业前景光明；股价上涨 nL6N3XT0JK ** Aardvark Therapeutics Inc AARD.O:BUZZ - 奥本海默将 Aardvark 评为 \"跑赢大盘\"，看好其差异化肥胖专营权。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nL4T3XT0UZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4127","LU0158827948.USD","LU1223083913.SGD","LU2168564495.EUR","NINE","HXHX","IE00B1XK9C88.USD","AME","SOC","BK4141","HL","LU0654597011.USD","CDE","EQT","PCLA","NRDY","AARD","FSLR","NOW","NUAI","RVPH","CNX","SGXZ81514606.USD","HIHO","IVVD","SOS","LU1992135472.HKD","HII","NEM","FCX","EXE","BK4139","AZO","LU0094547139.USD","LU0314106906.USD","LU0081259029.USD","SPRB","IE00B19Z9P08.USD","LU2211815571.USD","LU2458330169.SGD","LU0154245673.USD","SG9999015952.SGD","AFJK","GILD"],"gpt_icon":1},{"id":"2593349790","title":"BUZZ-奧本海默將 Aardvark 評為 \"跑贏大盤\"，看好其差異化肥胖專營權","url":"https://stock-news.laohu8.com/highlight/detail?id=2593349790","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593349790?lang=zh_tw&edition=fundamental","pubTime":"2025-12-23 20:25","pubTimestamp":1766492743,"startTime":"0","endTime":"0","summary":"BUZZ-奥本海默将 Aardvark 评为 \"跑赢大盘\"，看好其差异化肥胖专营权12月23日 - ** 券商奥本海默给予Aardvark Therapeutics AARD.O\"跑赢大盘 \"评级和35美元的目标价，这意味着该股较上一交易日收盘价有超过两倍的上涨空间。** 奥本海默认为，AARD公司即将推出的治疗PWS的实验性药物ARD-101的后期研究结果是一个重要催化剂，并认为与Soleno Therapeutics公司SLNO.O获得FDA批准的药物Vykat XR相比，ARD-101可能具有更好的安全性。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nL4T3XT0MU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLNO","AARD","BK4139"],"gpt_icon":0},{"id":"1119474932","title":"Aardvark Therapeutics Inc - 加拿大和英國的臨牀試驗地點已獲得註冊許可","url":"https://stock-news.laohu8.com/highlight/detail?id=1119474932","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119474932?lang=zh_tw&edition=fundamental","pubTime":"2025-12-11 05:24","pubTimestamp":1765401846,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics Inc - 加拿大和英国的临床试验地点已获得注册许可","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"1150804035","title":"Aardvark Therapeutics在澳大利亞進行的英雄三期試驗中宣佈首位患者接受治療","url":"https://stock-news.laohu8.com/highlight/detail?id=1150804035","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150804035?lang=zh_tw&edition=fundamental","pubTime":"2025-12-11 05:05","pubTimestamp":1765400713,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics在澳大利亚进行的英雄三期试验中宣布首位患者接受治疗","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"1194886481","title":"Aardvark Therapeutics宣佈FDA就擴大針對普拉德-威利綜合徵的三期Hero試驗人羣的協議修訂達成一致","url":"https://stock-news.laohu8.com/highlight/detail?id=1194886481","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194886481?lang=zh_tw&edition=fundamental","pubTime":"2025-10-08 20:02","pubTimestamp":1759924977,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics宣布FDA就扩大针对普拉德-威利综合征的三期Hero试验人群的协议修订达成一致","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"2572894145","title":"美國研究綜述-Carvana、Marvell Technology、Wayfair","url":"https://stock-news.laohu8.com/highlight/detail?id=2572894145","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572894145?lang=zh_tw&edition=fundamental","pubTime":"2025-10-01 15:33","pubTimestamp":1759304017,"startTime":"0","endTime":"0","summary":"美国研究综述-Carvana、Marvell Technology、Wayfair路透社10月1日 - 华尔街证券分析师周三调整了对几家美国上市公司的评级和目标价，其中包括 Carvana、Marvell Technology 和 Wayfair。* Marvell Technology Inc MRVL.O：TD Cowen 将其评级从买入下调至持有 * Pool Corp POOL.O：KeyBanc将其评级从行业权重调高至 \"买入\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251001:nL3S3VI0GJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTSI","PDM","POOL","LU0130102774.USD","IPG","NAVI","FOUR","BRO","CHYM","TOST","WU","LW","HROW","BILL","CPAY","UPWK","AXP","DEI","ZETA","BWIN","AARD","MRVL","ADSK","ALLY","LIF","SLM","ARCB","SMTC","AJG","CVNA","EEFT","PTGX","BLDR","AXSM","MMC","JKHY","SYF","MQ","PAYX","OMC","BSX","HHH","ZYME","MRCY","FIS","BFH"],"gpt_icon":1},{"id":"2572589411","title":"美國研究綜述-Carvana、Marvell Technology、Wayfair","url":"https://stock-news.laohu8.com/highlight/detail?id=2572589411","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572589411?lang=zh_tw&edition=fundamental","pubTime":"2025-10-01 15:33","pubTimestamp":1759304017,"startTime":"0","endTime":"0","summary":"美国研究综述-Carvana、Marvell Technology、Wayfair路透社10月1日 - 华尔街证券分析师周三调整了对几家美国上市公司的评级和目标价，其中包括 Carvana、Marvell Technology 和 Wayfair。* Marvell Technology Inc MRVL.O：TD Cowen 将其评级从买入下调至持有 * Pool Corp POOL.O：KeyBanc将其评级从行业权重调高至 \"买入\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251001:nL3T3VI0GJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MMC","BRO","CVNA","CHYM","SLM","LW","AJG","BILL","EEFT","MRCY","OMC","DEI","AXSM","POOL","AARD","PDM","ZYME","MQ","PAYX","IPG","TOST","NAVI","BWIN","LIF","MRVL","WU","FIS","JKHY","CPAY","BFH","BLDR","FOUR","ADSK","MTSI","ZETA","LU0130102774.USD","ARCB","ALLY","SMTC","HHH","SYF","UPWK","BSX","AXP","PTGX","HROW"],"gpt_icon":1},{"id":"2566931627","title":"LB 製藥公司在美國首次公開募股中籌資 2.85 億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2566931627","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566931627?lang=zh_tw&edition=fundamental","pubTime":"2025-09-11 09:18","pubTimestamp":1757553531,"startTime":"0","endTime":"0","summary":"更新版 1-LB 制药公司在美国首次公开募股中筹资 2.85 亿美元从第 2 段起增加详细信息路透社9月11日 - LB Pharmaceuticals 生物技术公司周三表示，该公司在美国首次公开募股中筹集了 2.85 亿美元，这是自 2 月份以来生物技术公司首次大规模公开募股。此次 IPO 对 LB 公司的估值为 3.015 亿美元。该公司股价自2月份上市以来已下跌近一半。该公司计划在 2026 年第一季度开始对急性精神分裂症患者进行为期六周的 LB-102 晚期试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250911:nL3S3UY031:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PIPR","BK4207","AARD","MNSH","SF","BK4127"],"gpt_icon":0},{"id":"2565680373","title":"生物技術行業陷入困境，LB Pharmaceuticals 着眼於 3.22 億美元的首次公開募股估值","url":"https://stock-news.laohu8.com/highlight/detail?id=2565680373","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565680373?lang=zh_tw&edition=fundamental","pubTime":"2025-09-08 22:37","pubTimestamp":1757342235,"startTime":"0","endTime":"0","summary":"生物技术行业陷入困境，LB Pharmaceuticals 着眼于 3.22 亿美元的首次公开募股估值路透社9月8日 - 资金短缺的药物开发商 LB Pharmaceuticals周一表示，其纽约首次公开募股的目标估值将高达 3.216 亿美元，这可能是几个月来美国生物技术公司首次大规模上市。公司背景 LB Pharmaceuticals 公司成立于 2015 年，目前正在开发针对精神分裂症、双相抑郁症和其他神经精神疾病的疗法。下一步计划LB Pharmaceuticals 将在纳斯达克上市，股票代码为 \"LBRX\"。Leerink Partners、Piper Sandler 和 Stifel 是此次发行的主承销商。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nL3S3UV13A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PIPR","BK4127","SF","BK4207","AARD","MNSH"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":11,"code":"91000000","status":"200"}]}}